When research using these two SSTR2 radiolabeled compounds were expanded to four advanced NET patients (134), the 177Lu-DOTA-JR11 provided 1.7–10.6-fold higher tumor uptake dose compared to the agonist, 177Lu-DOTA-octreotate, which resulted in a partial remission in half of the enrolled patients. The gene discussed is SSTR2; the disease is neoplasm.